 IGM Biosciences Inc IGMS has progressed two Phase 1 trials evaluating IGM-6268, an anti-SARS-CoV-2 IgM monoclonal antibody, to treat and prevent infection COVID-19. Get the Inside Access Traders Are Using to Profit More and Win Bigger. 